Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 84

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm

Bauer, Matthias R., Krämer, Andreas, Settanni, Giovanni, Jones, Rhiannon N., Ni, Xiaomin, Khan Tareque, Raysa, Fersht, Alan R., Spencer, John, Joerger, Andreas C.·2020·ACS Chemical Biology
DOI 10.1021/acschembio.9b00748
Open this paper in CoChat — free account

Abstract

We have previously shown that the thermolabile, cavity-creating p53 cancer mutant Y220C can be reactivated by small-molecule stabilizers. In our ongoing efforts to unearth druggable variants of the p53 mutome, we have now analyzed the effects of other cancer-associated mutations at codon 220 on the structure, stability, and dynamics of the p53 DNA-binding domain (DBD). We found that the oncogenic Y220H, Y220N, and Y220S mutations are also highly destabilizing, suggesting that they are largely unfolded under physiological conditions. A high-resolution crystal structure of the Y220S mutant DBD revealed a mutation-induced surface crevice similar to that of Y220C, whereas the corresponding pocket’s accessibility to small molecules was blocked in the structure of the Y220H mutant. Accordingly, a series of carbazole-based small molecules, designed for stabilizing the Y220C mutant, also bound to and stabilized the folded state of the Y220S mutant, albeit with varying affinities due to structural differences in the binding pocket of the two mutants. Some of the compounds also bound to and stabilized the Y220N mutant, but not the Y220H mutant. Our data validate the Y220S and Y220N mutants as druggable targets and provide a framework for the design of Y220S or Y220N-specific compounds as well as compounds with dual Y220C/Y220S specificity for use in personalized cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acschembio.9b00748

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 56

  1. Joerger, 2016, The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches, Annu. Rev. Biochem., 85, 375, 10.1146/annurev-biochem-060815-014710 · DOI · Paper page
  2. Khoo, 2014, Drugging the p53 pathway: understanding the route to clinical efficacy, Nat. Rev. Drug Discovery, 13, 217, 10.1038/nrd4236 · DOI · Paper page
  3. Stiewe, 2018, How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance, Drug Resist. Updates, 38, 27, 10.1016/j.drup.2018.05.001 · DOI
  4. Joerger, 2007, Structure-function-rescue: the diverse nature of common p53 cancer mutants, Oncogene, 26, 2226, 10.1038/sj.onc.1210291 · DOI · Paper page
  5. Freed-Pastor, 2012, Mutant p53: one name, many proteins, Genes Dev., 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
  6. Hainaut, 2016, Somatic TP53 Mutations in the Era of Genome Sequencing, Cold Spring Harbor Perspect. Med., 6, a026179, 10.1101/cshperspect.a026179 · DOI · Paper page
  7. Bullock, 2000, Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
  8. Wang, 2017, Multisite aggregation of p53 and implications for drug rescue, Proc. Natl. Acad. Sci. U. S. A., 114, E2634, 10.1073/pnas.1700308114 · DOI · Paper page
  9. Dearth, 2007, Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers, Carcinogenesis, 28, 289, 10.1093/carcin/bgl132 · DOI · Paper page
  10. Joerger, 2006, Structural basis for understanding oncogenic p53 mutations and designing rescue drugs, Proc. Natl. Acad. Sci. U. S. A., 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
  11. Boeckler, 2008, Targeted rescue of a destabilized mutant of p53 by an in silico screened drug, Proc. Natl. Acad. Sci. U. S. A., 105, 10360, 10.1073/pnas.0805326105 · DOI · Paper page
  12. Wilcken, 2012, Halogen-enriched fragment libraries as leads for drug rescue of mutant p53, J. Am. Chem. Soc., 134, 6810, 10.1021/ja301056a · DOI · Paper page
  13. Joerger, 2015, Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53, Structure, 23, 2246, 10.1016/j.str.2015.10.016 · DOI
  14. Bauer, 2016, Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs, ACS Chem. Biol., 11, 2265, 10.1021/acschembio.6b00315 · DOI
  15. Basse, 2010, Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant, Chem. Biol., 17, 46, 10.1016/j.chembiol.2009.12.011 · DOI · Paper page
  16. Wilcken, 2012, Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition, Proc. Natl. Acad. Sci. U. S. A., 109, 13584, 10.1073/pnas.1211550109 · DOI · Paper page
  17. Bauer, 2019, A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C, Future Med. Chem., 11, 2491, 10.4155/fmc-2019-0181 · DOI
  18. Liu, 2013, Small molecule induced reactivation of mutant p53 in cancer cells, Nucleic Acids Res., 41, 6034, 10.1093/nar/gkt305 · DOI · Paper page
  19. Baud, 2018, Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines, Eur. J. Med. Chem., 152, 101, 10.1016/j.ejmech.2018.04.035 · DOI
  20. Wassman, 2013, Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53, Nat. Commun., 4, 1407, 10.1038/ncomms2361 · DOI · Paper page
  21. Pradhan, 2019, Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket, Nucleic Acids Res., 47, 1637, 10.1093/nar/gky1314 · DOI
  22. Bykov, 2016, Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy, Front. Oncol., 6, 21, 10.3389/fonc.2016.00021 · DOI · Paper page
  23. Bauer, 2016, 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells, Proc. Natl. Acad. Sci. U. S. A., 113, E5271, 10.1073/pnas.1610421113 · DOI
  24. Blanden, 2015, Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore, Mol. Pharmacol., 87, 825, 10.1124/mol.114.097550 · DOI · Paper page
  25. Bouaoun, 2016, TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data, Hum. Mutat., 37, 865, 10.1002/humu.23035 · DOI · Paper page
  26. Leroy, 2013, The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis, Nucleic Acids Res., 41, D962, 10.1093/nar/gks1033 · DOI · Paper page
  27. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Ca-Cancer J. Clin., 68, 394, 10.3322/caac.21492 · DOI · Paper page
  28. Capponcelli, 2005, Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation, Hum. Mutat., 26, 94, 10.1002/humu.20192 · DOI
  29. Nikolova, 1998, Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability, Proc. Natl. Acad. Sci. U. S. A., 95, 14675, 10.1073/pnas.95.25.14675 · DOI · Paper page
  30. Joerger, 2004, Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations, J. Biol. Chem., 279, 1291, 10.1074/jbc.M309732200 · DOI · Paper page
  31. Ang, 2006, Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains, J. Biol. Chem., 281, 21934, 10.1074/jbc.M604209200 · DOI · Paper page
  32. Bienert, 2017, The SWISS-MODEL Repository-new features and functionality, Nucleic Acids Res., 45, D313, 10.1093/nar/gkw1132 · DOI · Paper page
  33. Interlandi, 2008, Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments, J. Mol. Biol., 375, 837, 10.1016/j.jmb.2007.09.042 · DOI
  34. Bissantz, 2010, A medicinal chemist’s guide to molecular interactions, J. Med. Chem., 53, 5061, 10.1021/jm100112j · DOI · Paper page
  35. Raghavan, 2019, Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics, Comput. Biol. Chem., 80, 398, 10.1016/j.compbiolchem.2019.05.005 · DOI
  36. Joerger, 2005, Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations, J. Biol. Chem., 280, 16030, 10.1074/jbc.M500179200 · DOI · Paper page
  37. Kabsch, 2010, Xds, Acta Crystallogr., Sect. D: Biol. Crystallogr., 66, 125, 10.1107/S0907444909047337 · DOI · Paper page
  38. Evans, 2006, Scaling and assessment of data quality, Acta Crystallogr., Sect. D: Biol. Crystallogr., 62, 72, 10.1107/S0907444905036693 · DOI · Paper page
  39. Evans, 2011, An introduction to data reduction: space-group determination, scaling and intensity statistics, Acta Crystallogr., Sect. D: Biol. Crystallogr., 67, 282, 10.1107/S090744491003982X · DOI · Paper page
  40. Winn, 2011, Overview of the CCP4 suite and current developments, Acta Crystallogr., Sect. D: Biol. Crystallogr., 67, 235, 10.1107/S0907444910045749 · DOI · Paper page
  41. Adams, 2010, PHENIX: a comprehensive Python-based system for macromolecular structure solution, Acta Crystallogr., Sect. D: Biol. Crystallogr., 66, 213, 10.1107/S0907444909052925 · DOI · Paper page
  42. Emsley, 2010, Features and development of Coot, Acta Crystallogr., Sect. D: Biol. Crystallogr., 66, 486, 10.1107/S0907444910007493 · DOI · Paper page
  43. Jorgensen, 1983, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys., 79, 926, 10.1063/1.445869 · DOI · Paper page
  44. Huang, 2017, CHARMM36m: an improved force field for folded and intrinsically disordered proteins, Nat. Methods, 14, 71, 10.1038/nmeth.4067 · DOI · Paper page
  45. Abraham, 2015, GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers, SoftwareX, 1, 19, 10.1016/j.softx.2015.06.001 · DOI · Paper page
  46. Budiman, 2007, Using molecular dynamics to map interaction networks in an aminoacyl-tRNA synthetase, Proteins: Struct., Funct., Genet., 68, 670, 10.1002/prot.21426 · doi:10.1002/prot.21426
  47. Godwin, 2017, Binding Site Configurations Probe the Structure and Dynamics of the Zinc Finger of NEMO (NF-kappaB Essential Modulator), Biochemistry, 56, 623, 10.1021/acs.biochem.6b00755 · DOI
  48. Nosé, 1984, A unified formulation of the constant temperature molecular dynamics methods, J. Chem. Phys., 81, 511, 10.1063/1.447334 · DOI · Paper page
  49. Hoover, 1985, Canonical dynamics: Equilibrium phase-space distributions, Phys. Rev. A: At., Mol., Opt. Phys., 31, 1695, 10.1103/PhysRevA.31.1695 · DOI · Paper page
  50. Parrinello, 1980, Crystal Structure and Pair Potentials: A Molecular-Dynamics Study, Phys. Rev. Lett., 45, 1196, 10.1103/PhysRevLett.45.1196 · DOI · Paper page
  51. Essmann, 1995, A smooth particle mesh Ewald method, J. Chem. Phys., 103, 8577, 10.1063/1.470117 · DOI · Paper page
  52. Hess, 1997, LINCS: A linear constraint solver for molecular simulations, J. Comput. Chem., 18, 1463, 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H · DOI · Paper page
  53. Humphrey, 1996, VMD: visual molecular dynamics, J. Mol. Graphics, 14, 33, 10.1016/0263-7855(96)00018-5 · DOI · Paper page
  54. Seeber, 2007, Wordom: a program for efficient analysis of molecular dynamics simulations, Bioinformatics, 23, 2625, 10.1093/bioinformatics/btm378 · DOI · Paper page
  55. Vanommeslaeghe, 2009, CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields, J. Comput. Chem., 31, 671, 10.1002/jcc.21367 · DOI · Paper page
  56. Brandt, 2012, Stability of p53 homologs, PLoS One, 7, e47889, 10.1371/journal.pone.0047889 · DOI · Paper page

Cited by

See all 84

Metadata

Authors
Bauer, M. R., Krämer, A., Settanni, G., Jones, R. N., Ni, X., Khan Tareque, R., Fersht, A. R., Spencer, J., & Joerger, A. C.
Affiliations
  • MRC Laboratory of Molecular Biology , Francis Crick Avenue, Cambridge Biomedical Campus , ,
  • Johann Wolfgang Goethe University , , Max-von-Laue-Str. 9 , , ,
  • Johannes Gutenberg University , , Staudingerweg 7 , ,
  • University of Sussex , , , ,
ORCID
Venue
ACS Chemical Biology
Publisher
American Chemical Society (ACS)
Published
2020-01-28
Volume
15
Issue
3
Pages
657-668
ISSN
  • 1554-8929
  • 1554-8937
DOI
10.1021/acschembio.9b00748
Cited by
84
References
1
Language
en
Licence
pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html (vor, 78 d)
Funders
  • Deutsche Forschungsgemeinschaft (JO 1473/1-1, SFB1066)
  • Worldwide Cancer Research (14-1002, 18-0043)
  • Max-Planck Graduate Center, University of Mainz (NA)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm. https://app.cochat.ai/papers/10.1021/acschembio.9b00748
The paper
Bauer, M. R., Krämer, A., Settanni, G., Jones, R. N., Ni, X., Khan Tareque, R., Fersht, A. R., Spencer, J., & Joerger, A. C. (2020). Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm. ACS Chemical Biology. https://doi.org/10.1021/acschembio.9b00748

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.